Organogenesis Holdings Inc. (ORGO) stock
Close on Nov 17, 2026Market cap $104.43MP/E –Yield –
Earnings
Organogenesis's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Organogenesis's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $45.50M | -69.8% | -$0.25 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026during market hours | $42.80M | -57.5% | -$0.77 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026during market hours | $36.30M | -58.1% | -$0.44 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026during market hours | $225.61M | +78.1% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025during market hours | $150.50M | +30.6% | $0.11 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | $100.80M | -22.6% | -$0.10 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025during market hours | $86.70M | -21.2% | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025during market hours | $126.70M | +27.1% | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024during market hours | $115.20M | +6.2% | $0.09 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024during market hours | $130.20M | +11.0% | -$0.13 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024during market hours | $110.00M | +2.2% | -$0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024during market hours | $99.70M | -13.7% | $0.00 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 9, 2023during market hours | $108.50M | -7.2% | $0.02 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023during market hours | $117.30M | -3.4% | $0.04 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023during market hours | $107.60M | +9.7% | -$0.02 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 1, 2023during market hours | $115.50M | -10.2% | $0.06 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022during market hours | $116.90M | +2.7% | $0.00 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022during market hours | $121.40M | – | $0.07 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022during market hours | $98.10M | – | $0.00 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 1, 2022during market hours | $128.60M | – | $0.39 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | $113.80M | – | $0.09 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 9, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 10, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 16, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 14, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Organogenesis's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total net revenue | FY2026 | $179.40M – $200.00M | – | New | Nov 5, 2026 |
| Total net revenue | FY2026 | $179.00M – $215.00M | $270.00M – $310.00M | Lowered | Aug 6, 2026 |
| Total net revenue decline | FY2026 | -52% – -45% | -38% – -25% | Lowered | May 7, 2026 |
Guidance vs results
The last range Organogenesis gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $500.00M – $525.00M | $563.61MΣ4Q | Above range |
| FY2025 | Revenue growth | +4% – +9% | +16.91%Σ4Q | Above range |
Guidance history
Every forecast Organogenesis put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Total net revenue | FY2026 | $179.40M – $200.00M | New |
| Aug 6, 2026 | Total net revenue | FY2026 | $179.00M – $215.00M | Lowered |
| May 7, 2026 | Total net revenue | FY2026 | $270.00M – $310.00M | Lowered |
| May 7, 2026 | Total net revenue decline | FY2026 | -52% – -45% | Lowered |
| Feb 26, 2026 | Total net revenue | FY2026 | $350.00M – $420.00M | New |
| Feb 26, 2026 | Total net revenue decline | FY2026 | -38% – -25% | New |
| Nov 6, 2025 | EBITDA | FY2025 | $19.10M – $41.90M | New |
| Nov 6, 2025 | Adjusted EBITDA | FY2025 | $45.50M – $68.30M | Raised |
| Nov 6, 2025 | Net product revenue from Advanced Wound Care products | FY2025 | +4% – +8% | New |
| Nov 6, 2025 | Net product revenue from Surgical & Sports Medicine products | FY2025 | +6% – +23% | Raised |
| Nov 6, 2025 | Net product revenue from Advanced Wound Care products | FY2025 | $470.00M – $490.00M | New |
| Nov 6, 2025 | Net product revenue from Surgical & Sports Medicine products | FY2025 | $30.00M – $35.00M | Lowered |
| Nov 6, 2025 | Net income | FY2025 | $8.60M – $25.40M | New |
| Nov 6, 2025 | adjusted net income | FY2025 | $21.50M – $38.40M | New |
| Nov 6, 2025 | Net product revenue | FY2025 | +4% – +9% | New |
| Nov 6, 2025 | Net product revenue | FY2025 | $500.00M – $525.00M | New |
| Aug 7, 2025 | EBITDA | FY2025 | $6.20M – $37.00M | New |
| Aug 7, 2025 | Adjusted EBITDA | FY2025 | $31.10M – $61.90M | Lowered |
| Aug 7, 2025 | Net income (loss) | FY2025 | -$6.40M – $16.40M | Lowered |
| Aug 7, 2025 | adjusted net income | FY2025 | $5.50M – $28.30M | Lowered |
| Aug 7, 2025 | Net product revenue | FY2025 | $480.00M – $510.00M | New |
| May 8, 2025 | EBITDA | FY2025 | $20.00M – $59.60M | Lowered |
| May 8, 2025 | Adjusted EBITDA | FY2025 | $43.60M – $83.20M | Raised |
| May 8, 2025 | Net income | FY2025 | $4.70M – $34.00M | Lowered |
| May 8, 2025 | adjusted net income | FY2025 | $15.30M – $44.60M | Reaffirmed |
| May 8, 2025 | Net revenue from Advanced Wound Care products growth | FY2025 | -1% – +10% | New |
| May 8, 2025 | Net revenue from Surgical & Sports Medicine products growth | FY2025 | +6% – +23% | Raised |
| May 8, 2025 | Net revenue | FY2025 | $480.00M – $535.00M | Reaffirmed |
| May 8, 2025 | Net revenue from Advanced Wound Care products | FY2025 | $450.00M – $500.00M | Lowered |
| May 8, 2025 | Net revenue from Surgical & Sports Medicine products | FY2025 | $30.00M – $35.00M | Lowered |
| Feb 27, 2025 | EBITDA | FY2025 | $27.00M – $66.60M | New |
| Feb 27, 2025 | Adjusted EBITDA | FY2025 | $43.60M – $83.20M | Raised |
| Feb 27, 2025 | Net revenue from Advanced Wound Care products | FY2025 | -1% – +10% | New |
| Feb 27, 2025 | Net revenue from Surgical & Sports Medicine products | FY2025 | +6% – +23% | Raised |
| Feb 27, 2025 | Net revenue from Advanced Wound Care products | FY2025 | $450.00M – $500.00M | New |
| Feb 27, 2025 | Net revenue from Surgical & Sports Medicine products | FY2025 | $30.00M – $35.00M | Lowered |
| Feb 27, 2025 | Net income | FY2025 | $9.50M – $38.80M | New |
| Feb 27, 2025 | adjusted net income | FY2025 | $15.30M – $44.60M | New |
| Feb 27, 2025 | Net revenue | FY2025 | $480.00M – $535.00M | New |
| Nov 12, 2024 | EBITDA | FY2024 | -$1.30M – $14.40M | Lowered |
| Nov 12, 2024 | Adjusted EBITDA | FY2024 | $31.70M – $47.40M | Raised |
| Nov 12, 2024 | Net loss | FY2024 | -$12.30M – -$600.00K | Raised |
| Nov 12, 2024 | adjusted net income | FY2024 | $6.70M – $18.40M | Raised |
| Nov 12, 2024 | Net revenue year-over-year increase | FY2024 | +5% – +11% | New |
| Nov 12, 2024 | Net revenue | FY2024 | $455.00M – $480.00M | Raised |
| Aug 8, 2024 | EBITDA | FY2024 | -$17.00M – $2.00M | Lowered |
| Aug 8, 2024 | Adjusted EBITDA | FY2024 | $16.00M – $35.00M | Raised |
| Aug 8, 2024 | Net loss | FY2024 | -$27.00M – -$12.00M | Lowered |
| Aug 8, 2024 | adjusted net income (loss) | FY2024 | -$8.00M – $7.00M | Narrowed |
| Aug 8, 2024 | Net revenue | FY2024 | $445.00M – $470.00M | Reaffirmed |
| May 9, 2024 | EBITDA | FY2024 | $5.80M – $25.00M | Lowered |
| May 9, 2024 | Adjusted EBITDA | FY2024 | $15.80M – $35.00M | Raised |
| May 9, 2024 | Net (loss) income | FY2024 | -$10.60M – $4.60M | Reaffirmed |
| May 9, 2024 | adjusted net (loss) income | FY2024 | -$8.10M – $7.10M | Reaffirmed |
| May 9, 2024 | Net revenue | FY2024 | $445.00M – $470.00M | New |
| Feb 29, 2024 | EBITDA | FY2024 | $5.80M – $25.00M | New |
| Feb 29, 2024 | Adjusted EBITDA | FY2024 | $15.80M – $35.00M | New |
| Feb 29, 2024 | Net income (loss) | FY2024 | -$10.60M – $4.60M | New |
| Feb 29, 2024 | adjusted net income (loss) | FY2024 | -$8.10M – $7.10M | New |
| Feb 29, 2024 | Net revenue | FY2024 | $445.00M – $470.00M | New |
| Nov 9, 2023 | EBITDA | FY2023 | $26.00M – $37.00M | New |
| Nov 9, 2023 | Adjusted EBITDA | FY2023 | $40.00M – $51.00M | Raised |
| Nov 9, 2023 | Net income | FY2023 | $4.00M – $9.00M | Narrowed |
| Nov 9, 2023 | adjusted net income | FY2023 | $11.00M – $17.00M | Raised |
| Nov 9, 2023 | Net revenue | FY2023 | $433.00M – $446.00M | New |
| May 10, 2023 | EBITDA | FY2023 | $28.00M – $39.00M | Lowered |
| May 10, 2023 | Adjusted EBITDA | FY2023 | $38.00M – $49.00M | Raised |
| May 10, 2023 | Net income | FY2023 | $3.00M – $11.00M | Lowered |
| May 10, 2023 | adjusted net income | FY2023 | $8.00M – $16.00M | Lowered |
| May 10, 2023 | Net revenue | FY2023 | $454.00M – $466.00M | Raised |
| Mar 1, 2023 | EBITDA | FY2023 | $26.60M – $36.10M | New |
| Mar 1, 2023 | Adjusted EBITDA | FY2023 | $36.50M – $46.00M | Raised |
| Mar 1, 2023 | Net income | FY2023 | $7.20M – $13.90M | New |
| Mar 1, 2023 | adjusted net income | FY2023 | $12.30M – $19.00M | New |
| Mar 1, 2023 | Net revenue | FY2023 | $450.00M – $462.00M | New |
| Nov 9, 2022 | EBITDA | FY2022 | $31.00M – $42.00M | Lowered |
| Nov 9, 2022 | Adjusted EBITDA | FY2022 | $46.00M – $58.00M | Lowered |
| Nov 9, 2022 | Net income | FY2022 | $12.00M – $20.00M | Lowered |
| Nov 9, 2022 | adjusted net income | FY2022 | $22.00M – $31.00M | Lowered |
| Nov 9, 2022 | Net revenue | FY2022 | $448.00M – $465.00M | Lowered |
| Aug 9, 2022 | EBITDA | FY2022 | $49.00M – $63.00M | Lowered |
| Aug 9, 2022 | Adjusted EBITDA | FY2022 | $60.00M – $74.00M | Lowered |
| Aug 9, 2022 | Net income | FY2022 | $26.00M – $36.00M | Lowered |
| Aug 9, 2022 | adjusted net income | FY2022 | $33.00M – $43.00M | Lowered |
| Aug 9, 2022 | Net revenue | FY2022 | $465.00M – $490.00M | Raised |
| May 10, 2022 | EBITDA | FY2022 | $70.30M – $85.70M | Lowered |
| May 10, 2022 | Adjusted EBITDA | FY2022 | $79.90M – $95.30M | Raised |
| May 10, 2022 | Net income | FY2022 | $41.20M – $52.70M | Lowered |
| May 10, 2022 | adjusted net income | FY2022 | $47.30M – $58.80M | Lowered |
| May 10, 2022 | Net revenue | FY2022 | $485.00M – $515.00M | Reaffirmed |
| May 10, 2022 | Net revenue from Advanced Wound Care products | FY2022 | $455.00M – $481.00M | Lowered |
| May 10, 2022 | Net revenue from Surgical & Sports Medicine products | FY2022 | $30.00M – $34.00M | Lowered |
| May 10, 2022 | Net revenue from the sale of PuraPly products | FY2022 | $207.00M – $217.00M | Raised |
| Mar 1, 2022 | EBITDA | FY2022 | $73.50M – $88.90M | New |
| Mar 1, 2022 | Adjusted EBITDA | FY2022 | $79.90M – $95.30M | New |
| Mar 1, 2022 | Net income | FY2022 | $56.50M – $71.50M | New |
| Mar 1, 2022 | adjusted net income | FY2022 | $60.20M – $75.20M | New |
| Mar 1, 2022 | Net revenue | FY2022 | $485.00M – $515.00M | New |
| Nov 9, 2021 | Net revenue | FY2021 | $458.00M – $470.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Organogenesis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- News
- News
- Results
- Results
See a number that looks wrong?